UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2022
Commission File Number: 001-39992
Immunocore Holdings plc
(Translation of registrant’s name into English)
92 Park Drive
Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
Press Release
On March 3, 2022, Immunocore Holdings plc (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended
December 31, 2021. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 6-K.
Letter to Shareholders
On March 3, 2022, the Company issued a letter to shareholders. A copy of the letter to shareholders is furnished herewith as Exhibit 99.2 to this Report on
Form 6-K.
EXHIBIT INDEX
|
Exhibit
No.
|
|
Description
|
| |
|
|
|
|
|
Press Release dated March 3, 2022.
|
| |
|
|
|
|
|
Letter to Shareholders dated March 3, 2022.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
| |
IMMUNOCORE HOLDINGS PLC
|
| |
|
|
|
Date: March 3, 2022
|
By:
|
/s/ Bahija Jallal, Ph.D.
|
| |
|
Name
|
Bahija Jallal, Ph.D.
|
| |
|
Title:
|
Chief Executive Officer
|